pharmaphorum
MAY 27, 2022
Digital health company Akili Interactive has agreed a deal that could see its gamified therapy for attention-deficit hyperactivity disorder (ADHD) hosted on the creative gaming platform Roblox, used by around 55 million users worldwide. First launched in 2006, Roblox is an online space where users can play games – more than 20 million of them at a recent count – created by developers and individuals.
OctariusRx
MAY 27, 2022
This Memorial Day we give thanks and honor those who made the ultimate sacrifice for our country! “It is foolish and wrong to mourn the men who died. Rather we should thank God such men lived.” – George S. Patton. The OctariusRx team wishes you a peaceful and blessed Memorial Day! From the bottom of our hearts, thank you to all those who served and gave their lives for our freedom, and the families who supported their heroic efforts.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
MAY 27, 2022
This is the second in a two-part series examining how pharma can embrace the DEI agenda to create more effective medicines through more representative clinical trials. You can read part one of this article here. As the shift to home working proliferated during the pandemic, work became decentralised – and many businesses were able to be productive with a workforce at home.
Pharma Times
MAY 27, 2022
Initial group of patients have received Saphnelo in a phase 3 trial evaluating lupus nephritis
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
pharmaphorum
MAY 27, 2022
Roche will present the new data at next week’s ASCO congress showing that its bispecific antibody glofitamab can achieve high and durable responses in patients with aggressive lymphoma. The results of the phase 2 NP30179 study will be presented for the first time at ASCO, involving 107 patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who had received a median of three prior therapies.
Pharma Times
MAY 27, 2022
Faricimab is administered as an eye injection with an interval of up to 16 weeks
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
pharmaphorum
MAY 27, 2022
Accelerating the Discovery, Translation & Large-Scale Manufacturing of Exosomes & EVs. With 3 days of unrivaled content and two dedicated tracks, this year’s summit will be putting the spotlight on cutting-edge strategies from discovery, translation, and clinical development of modified and unmodified exosomes and EVs, to accelerate this emerging field forward.
pharmaphorum
MAY 27, 2022
The 13 th Annual World Multispecific Summit will deliver a greater scope and penetration of innovative technical content than any other meeting. This year’s re-imagined agenda will cover unique target discovery, mechanistic diversity and translational science as well as novel formats, product design and manufacturability challenges faced in the bispecific field.
pharmaphorum
MAY 27, 2022
Capturing an audience is a critical task. Doing that in a wind tunnel of multi-channel white noise requires a special brand of cut-through. The standard operating procedures that guided practice for a generation were ripped up by the pandemic and the challenges for pharmaceutic company field force teams multiplied while the opportunities diminished.
pharmaphorum
MAY 27, 2022
Johnson & Johnson and Legend Biotech will arrive at next week’s ASCO congress with a new EU approval for multiple myeloma CAR-T Carvykti. The European Commission has cleared Carvykti (ciltacabtagene autoleucel or cilta-cel) as a treatment for adults with relapsed and refractory multiple myeloma who have received at least three prior therapies and whose cancer is worsening.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Expert insights. Personalized for you.
93 
Let's personalize your content